{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:37:53Z","timestamp":1793241473601,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The relationship between daily dose, serum concentrations, and clinical outcomes of olanzapine as well as the influencing factors thereof in children and adolescents treated for different psychiatric disorders were investigated in daily clinical practice. In addition, it was examined whether the current recommended therapeutic range (TR) for adult patients with psychotic disorders is valid for minors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The Competence Network for Therapeutic Drug Monitoring (www.tdm-kjp.com) routinely collects demographic and clinical outcome data as well as serum concentrations of children and adolescents treated with psychotropics. The therapeutic effect is documented using the Clinical Global Impression Scale subscale for Global Improvement. Adverse drug reactions (ADRs) are assessed using the Udvalg for Kliniske Undersogelser\u2013Side Effect Rating Scale.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One hundred fifteen patients (mean age = 15.9 years; range = 10.4\u201318.8 years; 40.9% male) were included. The majority (72.1%) was cotreated with other psychotropic drugs. A positive medium linear relationship (r = 0.619; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) between olanzapine dose (mean = 11.64 mg\/d) and serum concentration (mean = 35.65 ng\/mL) was found with a marked interindividual variability of serum concentrations. Neither relationship between olanzapine serum concentration and treatment response (clinical benefit documented in 80%) nor ADRs (documented in 53.3%, in 7.5% judged as severe) was detected. Most of the patients with psychotic and eating disorders (68.8% and 71.8%, respectively) had an olanzapine serum concentration within the TR suggested for adults.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>There are several limitations of this study because of the naturalistic design, and our results should therefore be interpreted with caution. As most of the patients showed a clinical benefit under olanzapine concentrations within the TR for adults and only a minority had severe ADRs, it is reasonable to conclude a similar TR for children, adolescents, and adults.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000398","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T19:44:57Z","timestamp":1491507897000},"page":"273-281","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice"],"prefix":"10.1097","volume":"39","author":[{"given":"Stefanie","family":"Fekete","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wewetzer","sequence":"additional","affiliation":[{"name":"Clinics of City Cologne GmbH, Child and Adolescent Psychiatry and Psychotherapy, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mehler-Wex","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"},{"name":"Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany;"},{"name":"Hemera Private Hospital for Mental Health-Adolescents and Young Adults, Bad Kissingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Holtkamp","sequence":"additional","affiliation":[{"name":"DRK, Clinic of Child and Adolescent Psychiatry, Psychotherapy\/Psychosomatics, Bad Neuenahr, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Burger","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic Drug Monitoring, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Reichert","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Taurines","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Romanos","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gerlach","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Egberts","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Centre for Mental Health, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/cap.2006.0137","article-title":"Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study","volume":"18","author":"Dittmann","year":"2008","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","article-title":"A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder","volume":"11","author":"Frazier","year":"2001","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00004714-199712000-00006","article-title":"Olanzapine plasma concentrations and clinical response in acutely III schizophrenic patients","volume":"17","author":"Perry","year":"1997","journal-title":"J Clin Psychopharmacol."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled study of olanzapine in childhood\/adolescent pervasive development disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","article-title":"Effective open-label treatment of tourette's disorder with olanzapine","volume":"15","author":"Stamenkovic","year":"2000","journal-title":"Int Clin Psychopharmacol."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v65n1106","article-title":"An open trail of olanzapine in anorexia nervosa","volume":"65","author":"Barbarich","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/eat.10115","article-title":"Olanzapine use an adjunctive treatment for hospitalized children with anorexia nervosa: case reports","volume":"33","author":"Boachie","year":"2003","journal-title":"Int J Eat Disord."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e328080ca31","article-title":"Olanzapine therapy in anorexia nervosa: psychobiological effects","volume":"22","author":"Brambilla","year":"2007","journal-title":"Clin Psychopharmacol."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s007870170039","article-title":"Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases","volume":"10","author":"Mehler","year":"2001","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/j.1440-1665.2004.02154.x","article-title":"Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa","volume":"13","author":"Mondraty","year":"2005","journal-title":"Australas Psychiatry."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/cap.2010.0131","article-title":"Olanzapine Use for the adjunctive treatment of adolescents with anorexia nervosa","volume":"21","author":"Norris","year":"2011","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1024\/1422-4917.34.1.5","article-title":"Therapeutic drug monitoring in child and adolescent psychiatry-practical recommendations [in German]","volume":"34","author":"Gerlach","year":"2006","journal-title":"Z Kinder Jugendpsychiatr Psychother."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.0045","article-title":"Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents","volume":"17","author":"Aichhorn","year":"2007","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0031-1286291","article-title":"Therapeutic drug monitoring in child and adolescent psychiatry","volume":"44","author":"Egberts","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1753-2000-3-14","article-title":"Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy","volume":"3","author":"Mehler-Wex","year":"2009","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2000","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"Theisen","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R25-20230928","first-page":"26","article-title":"Therapeutic drug monitoring in children and adolescents treated with second-generation antipsychotics in daily clinical practice","author":"Egberts","year":"2016","journal-title":"Pharmacopsychiatry."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00007691-200408000-00019","article-title":"Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service","volume":"26","author":"Heller","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00702-016-1573-y","article-title":"Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice","volume":"123","author":"Wohkittel","year":"2016","journal-title":"J Neural Transm."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"Skogh","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815527","article-title":"Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients","volume":"37","author":"Bergemann","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/FTD.0b013e3181633429","article-title":"Large intraindividual variability of olanzapine serum concentrations in adolescent patients","volume":"30","author":"Bachmann","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00004714-200210000-00010","article-title":"Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects","volume":"22","author":"Hiemke","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","article-title":"Pharmacogenetics, drug-metabolizing enzymes, and clinical practice","volume":"58","author":"Gardiner","year":"2006","journal-title":"Pharmacol Rev."},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"545","DOI":"10.31887\/DCNS.2014.16.4\/spreskorn","article-title":"Prediction of individual response to antidepressants and antipsychotics: an integrated concept","volume":"12","author":"Preskorn","year":"2014","journal-title":"Dialogues Clin Neurosci."},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia","volume":"20","author":"Grothe","year":"2000","journal-title":"J Clin Psychopharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:04:45Z","timestamp":1695863085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201706000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000398","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}